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  Background: RAS mutations have been shown to confer resistance to anti-EGFR 
treatment. We analyzed the results of the PETACC8 trial (cetuximab + FOLFOX vs 
FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III 
colon cancer.  
Methods: Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were 
sequenced using the Ampliseq colon-lung cancer panel version 2, in PETACC8 trial 
pts who consented to translational research.  The impact of cetuximab on time to 
recurrence (TTR), disease-free survival (DFS) and overall survival (OS) was 
investigated in pts with tumors harboring RAS & BRAF WT and RAS mutations. The 
prognostic value of each individual mutation was also tested.  
Results:  Among the 2559 pts analyzed, 745 pts (29%) were known to have KRAS 
exon 2 mutations and 163 pts (6.4%) the BRAF V600E mutation. Of the remaining 
1651 pts, 1054 were assessed by NGS, showing that a further 227 pts (21%) had 
KRAS exon 2,3,4 or NRAS exon 2,3,4 mutations, and that 46 pts (4.4%) had a newly 
diagnosed BRAF mutation. Cetuximab added to FOLFOX did not significantly 
improve TTR, DFS or OS in pts with RAS WT or RAS & BRAF WT tumors (HR 0.77 
to 1.03, all P>0.05). Cetuximab addition was not either significantly deleterious in 
RAS mutant pts or in pts with rare RAS or BRAF mutations. In the overall trial 
population, NRAS and KRAS codon 61 mutations were the only rare mutations with 
the same pejorative prognostic value as KRAS exon 2 or BRAF V600E mutations.  
Conclusion 
Though not significant, the clinically relevant 0.76 adjusted HR observed for DFS in 
favor of adding cetuximab to FOLFOX, in full RAS and BRAF WT stage III colon 
  cancer pts, may justify a new randomized controlled trial testing EGFR inhibitors in 
this setting.  
 
Clinical trial number: This is an ancillary study of the PETACC8 trial: EUDRACT 
2005-003463-23.  
Keywords: stage III colon cancer; RAS mutations; BRAF mutations; cetuximab; 
FOLFOX; phase III; adjuvant; prognosis 
Key message: In 1900 stage III colon cancer patients fully characterized by NGS for 
RAS and BRAF, adding cetuximab to the standard FOLFOX results in a trend to a 
better outcome in RAS & BRAF wildtype patients. Though not significant, the 
clinically relevant 0.76 adjusted/HR observed for DFS in favor of adding cetuximab 
may justify a new randomized trial with anti-EGFRs in this setting.  
  Introduction 
The Pan-European Trials in Alimentary traCt Cancer 8 (PETACC-8) study tested 
FOLFOX4, with or without cetuximab, after curative resection of stage III colon 
cancer [1]. Promising phase II and III studies of cetuximab adjunction to FOLFOX4 in 
metastatic colorectal cancer showed impressive response and disease-control rates, 
suggesting possible synergy of this new combination [2, 3]. The PETACC-8 protocol 
was amended on 17 June 2008, restricting enrolment to patients with KRAS exon 2 
WT tumours and increasing the sample size. The first analysis of the trial results was 
negative, with no improvement in disease-free survival (DFS) or overall survival (OS) 
when cetuximab was added to FOLFOX [1]. 
KRAS exon 2 mutations are predictive of resistance to anti–epidermal growth factor 
receptor (EGFR) therapy in patients with metastatic colorectal cancer [3-6], as are 
activating mutations in KRAS exon 3 or 4 and in NRAS exon 2, 3 or 4 [7, 8].  
BRAF mutations are typically exclusive of RAS mutations, and clinical data suggest 
that the BRAF V600E mutation is predictive of poorer survival but not of anti-EGFR 
efficacy in patients with metastatic colorectal cancer [9, 10], however, the low 
prevalence of these mutations makes it difficult to evaluate their possible biomarker 
status. 
Patient selection based on tumour mutational status might thus improve the harm-
benefit profile of anti-EGFR therapy. This has been largely demonstrated in 
metastatic colorectal cancer [7, 8] but not yet in the adjuvant setting. We and others 
recently found that BRAF V600E and KRAS exon 2 mutations were prognostic in 
stage III colon cancer, being associated with shorter time to recurrence (TTR), OS, 
and survival after relapse [11-14]. However, anti-EGFR efficacy has not yet been 
evaluated in selected patients with RAS WT and BRAF WT resected stage III colon 
  cancer.  
We used the Ampliseq colon-lung cancer panel version 2 to sequence exons 2, 3 
and 4 of KRAS and NRAS, as well as BRAF exons 11 and 15, amongst those 
PETACC8 trial participants who consented to translational research. TTR, DFS and 
OS were analyzed in full RAS WT patients and full RAS and BRAF WT patients. The 
prognostic impact of individual rare RAS and BRAF mutations was also investigated. 
 
Materials and methods 
Patients 
PETACC8 trial participants underwent complete resection of histologically proven 
stage III colon adenocarcinoma, and were then randomly assigned to receive 6 
months of either FOLFOX or FOLFOX+cetuximab, with regular monitoring, as 
described elsewhere [1]. The trial started in December 2005. The protocol was 
amended in June 2008 to enroll only patients with KRAS exon 2 WT tumours, and 
the sample size was increased to maintain power of statistical analyses. The study 
ended on 9 November 2009. Specific written informed consent was required from 
each patient included in the planned translational program of the trial.  
 
DNA Extraction and Mutation Analysis 
Tumour samples were prospectively banked. Tumour DNAs were extracted from 
FFPE tissues containing more than 50% of tumour cells by using the QIAamp® DNA 
Mini Kit (Qiagen®). Molecular analysis, centralised at Georges Pompidou European 
Hospital, was performed retrospectively for the 2096 patients included before the trial 
amendment and prospectively for the other 463 patients. KRAS hotspot mutations 
  (c.34G>A/p.G12S, c.34G>C/p.G12R, c.34G>T/p.G12C, c.35G>A/p.G12D, 
c.35G>C/p.G12A, c.35G>T/p.G12V and c.38G>A p.G13D) and the BRAF V600E 
mutation (c.1799T>A/p.V600E) were detected by real-time PCR with TaqMan® 
probes (Applied Biosystems). The assays are alteration-specific and robustly detect 
10% of mutated alleles for all the mutations tested. 
Exons 2, 3 and 4 of KRAS and NRAS, as well as BRAF exons 11 and 15, were 
sequenced with the Ampliseq colon-lung cancer panel version 2 in the PETACC8 trial 
participants who consented to translational research.  
Statistical Analyses 
TTR, DFS and OS were analysed in patients with any RAS or BRAF mutations, RAS 
& BRAF WT status, and rare RAS mutations. The individual prognostic value of each 
mutation was also analysed.  
TTR was defined as the time between randomization and local or metastatic 
recurrence or death related to disease recurrence, whichever occurred first. DFS was 
defined as the time between randomization and local or metastatic recurrence or 
diagnosis of a second colorectal cancer, or death from any cause, whichever 
occurred first. OS was defined as the time between randomization and death from 
any cause.  
For baseline comparisons, categorical factors were compared with χ2 tests and 
continuous factors with standard parametric or non-parametric tests, depending on 
their normality. Continuous variables are reported as mean (SD) and median 
(interquartile range, IQR) values.   
  TTR, DFS and OS curves were estimated using the Kaplan–Meier method. 
Differences between groups of patients were analysed with log-rank tests. Cox 
models, Kaplan-Meier curves and forest plots were used for all analyses.  Factors 
included in multivariate analyses were the treatment group and baseline prognostic 
factors that were clinically relevant or significant in univariate analysis, namely 
tumour grade, pT stage, pN stage, venous embolism, lymphatic invasion (VELI), 
bowel obstruction/perforation, and tumour location. 
A two-sided significance level of 5% was applied for all analyses. Results were not 
adjusted for multiple comparisons. All statistical analyses were done by FFCD 
statisticians using SAS statistical software (version 9.4). The database was locked in 
July 2015. 
 
Results 
Study population 
Among the 2559 patients included in the PETACC8 phase III study, 741 were KRAS 
exon 2 mutated and 167 were BRAF V600E mutated. Of the remaining 1651 patients, 
1054 gave their written consent for translational research and had sufficient tumour 
material for NGS analyses. NGS failed in 62 cases. The remaining 992 patients were 
fully analysed. A total of 1900 patients (including RAS mutated patients) met all the 
criteria for full molecular analysis (informed consent, sufficient material, and technical 
success) (Supplementary Figure 1). The patients' baseline and tumour 
characteristics are summarized in Table 1. The demographic and clinical 
characteristics of the patients included in the molecular study (N=1900) were not 
  significantly different from those of the entire randomized population (N=2559) 
(Supplementary Table 1). 
 
RAS and BRAF mutational status  
Amongst the 1900 patients included in the molecular study, 719 (38%) were double 
wildtype, 968 (51%) were RAS mutated and 213 (11%) were BRAF mutated (Figure 
1). KRAS, NRAS and BRAF mutation frequencies are summarized in Figure 1. 
The most frequently mutated KRAS exon was exon 2 (80.9%), followed by exons 4 
(8.3%) and 3 (4.6%); two tumours (0.2%) were mutated on two different exons (Table 
2). As expected, codon 12 was the most frequently mutated codon (75.9%), followed 
by codon 13 (18.4%). NRAS exons 2, 3 (codon 61) and 4 were mutated in 
respectively 30, 31 and 2 cases.  
BRAF was mutated in 213 tumours, including 192 tumours (90%) harbouring the 
V600E mutation. The second most frequent mutation affected codon 469, in 8 cases 
(3.8%). The mutations were grouped for analysis into V600E and non V600E.  
KRAS and BRAF mutations were both present in 8 tumours (4 V600E and 4 non 
V600E). KRAS and NRAS mutations were both present in two tumours (KRAS 
pA146T associated with NRAS p.G12D and with NRAS p.A146V in one case each). 
NRAS and BRAF mutations were both present in 3 tumours, all with non V600E 
BRAF mutations.  
Clinical outcomes according to RAS and BRAF mutational status  
  As previously reported, adding cetuximab to FOLFOX did not improve TTR in the 
whole trial population [1] (Figure 2-A). In the RAS WT and BRAF WT population, a 
trend towards better outcomes was seen in the cetuximab group but the difference 
did not reach statistical significance for TTR (HR:0.77 (0.55-1.08); P=0.12) (Figure 2-
B), DFS (HR:0.85 (0.63-1.14); P=0.27) or OS (HR:1.03 (0.70-1.50); P=0.89).  In 
multivariate analyses, the results were better but still not significant: TTR (HR=0.70 
(95%CI: 0.48 - 1.03); P=0.07), DFS (HR=0.76 (95%CI: 0.54 - 1.06); P=0.11), and OS 
(HR=0.90 (95%CI: 0.59 - 1.36); P=0.60). 
In patients with RAS-mutated tumours, the addition of cetuximab to FOLFOX was 
associated with a trend towards poorer TTR (HR:1.14 (0.91-1.44); P=0.25) (Figure 2-
C), DFS (HR:1.13 (0.91-1.40); P=0.27) and OS (HR:1.29 (0.99-1.69); P=0.061). 
These trends were less pronounced in multivariate analyses: TTR (HR=1.09 (95%CI: 
0.84 - 1.41); P=0.51), DFS (HR=1.06 (95%CI: 0.83 - 1.35); P=0.64), OS (HR= 1.17 
(95%CI: 0.87 - 1.57); P=0.30). 
As DFS is the usual endpoint for adjuvant trials, DFS Kaplan Meier curves are shown 
in supplementary figure 2-A, 2-B and 2-C. 
Rare RAS and BRAF mutations (i.e. KRAS exon 3,4 ; NRAS exon 2,3,4 and BRAF 
non V600E) tended to be associated with a deleterious effect of cetuximab, with HRs 
of 1.6 for TTR (P=0.09) and 1.61 for OS (P=0.13).  
 
Prognostic value of RAS and BRAF mutations 
In the overall study population, KRAS exon 2 and BRAF V600E mutations were 
associated with worse outcomes when compared to RAS and BRAF WT status, as 
  previously described [12]. This was also the case of KRAS and NRAS (exon 3) 
codon 61 rare mutants with respect to TTR  and OS, contrary to other rare RAS or 
BRAF mutants (Figure 3). 
The number of rare mutations was too small for meaningful multivariable analysis. 
 
Discussion  
 
KRAS and NRAS are closely related to RAS oncogene family members, and 
mutations at codon 12, 13, 61, 117 or 146 of either gene result in increased levels of 
guanosine triphosphate–bound RAS proteins [15, 16]. KRAS and NRAS mutations at 
these codons tend to be mutually exclusive in colorectal tumours, suggesting 
functional redundancy [17]. Mutations in HRAS, the third member of the RAS family, 
are infrequent in colorectal cancer [17, 18]. Clinical data suggest that RAS genes 
mutations are also associated with worse outcomes in the adjuvant setting [11-14]. 
Previous trials of anti-EGFR therapies combined with irinotecan or oxaliplatin-
containing regimens showed no benefit in patients with KRAS exon 2 mutations [2, 6]. 
Randomized phase 3 trials of panitumumab, given alone [19] or in combination with 
FOLFOX or FOLFIRI [3, 5, 7], showed no response to this anti-EGFR therapy in 
patients with metastatic colorectal tumours harboring a mutation in KRAS or NRAS. 
This was also the case in recent analyses of randomized trials with cetuximab [8, 20].  
All these studies involved patients with metastatic colorectal cancer. By contrast, we 
assessed here the effect of adjuvant cetuximab plus FOLFOX in patients with fully 
resected primary stage III colon tumours and full KRAS, NRAS and BRAF 
characterization.  
  Removing patients with rare RAS and BRAF mutations, with a poor outcome, from 
the target efficacy population reveals a trend to a positive effect of the addition of 
cetuximab to standard FOLFOX in patients with RAS & BRAF wildtype tumours. 
Although the impact of cetuximab was not statistically significant, it might be clinically 
relevant. In the MOSAIC pivotal trial, adding oxaliplatin to 5-FU improved DFS, with 
an HR of 0.8. Here, multivariate analysis adjusted for pT, pN, histological grade, VELI 
and tumour location yielded an HR of 0.76 (95%CI:0.54-1.06). This suggests that a 
new randomized trial powered to demonstrate such a difference in wildtype colon 
cancer patients may be relevant, especially after a 12-year period with no advances 
in adjuvant treatment of stage III colon cancer. If such trial is not forthcoming, our 
results would have to be confirmed using at least internally (other sequencing 
approaches for example) and externally (on other datasets) before discussing any 
practice change. New markers of colon cancer sensitivity to anti-EGFRs are 
emerging and could in future also be assessed in samples from PETACC8 and other 
adjuvant trials of anti-EGFRs, such as the NCCTG N0147 study, in order to generate 
hypotheses for future trials [21, 22]. 
Although adding cetuximab to FOLFOX tended to be beneficial in terms of TTR and 
DFS, this was not the case for OS (HR of 0.9 in adjusted analyses). This discordance 
between OS and TTR/DFS suggests that survival after relapse may differ between 
patients who do and do not receive adjuvant cetuximab, possibly because of lower 
cetuximab prescription rates in the metastatic setting when patients have received 
adjuvant cetuximab. Further analyses of survival after recurrence, and of treatments 
received at recurrence, are needed to clarify this point. 
A deleterious effect of cetuximab and panitumumab has been reported in some 
patients with RAS-mutated tumours treated with FOLFOX in the metastatic setting [7, 
  20]. This was not the case of patients with RAS-mutated metastatic colorectal 
cancer receiving irinotecan-based backbone chemotherapy [8]. In our study of stage 
III colon cancer, there was only a non-significant trend towards worse outcomes with 
cetuximab in RAS-mutant patients. 
This trend towards a deleterious effect of cetuximab was even stronger in patients 
with rare RAS mutations, but again it did not reach statistical significance, possibly 
owing to the small number of patients with rare RAS mutations (n=185).  
 
We and others have shown that KRAS exon 2 and BRAF V600E mutations are 
associated with a poor prognosis in stage III colon cancer and especially in the 90% 
of patients with MSS tumours [14]. However, the prognostic value of rare KRAS, 
NRAS and BRAF mutations has rarely been studied in this setting. Gavin et al 
reported in 2299 stage II and III colon tumours a similar frequency of NRAS 
mutations (2.9%) that were associated with a worse TTR (HR=1.53; 95%CI, 1.01-
2.31; P=0.04), but this difference disappeared in multivariate analysis and was not 
significant for OS [23]. A recent retrospective study of rare KRAS mutations at 
codons 12, 13 and 61 in stage II-III colon cancer patients showed no significant 
impact on DFS or OS [24]. However, the impact of individual KRAS mutations was 
not studied, the sample was quite small, and the study was retrospective. Modest et 
al. very recently studied the prognostic impact of RAS mutations in metastatic 
patients and found that only G13D and G12C had prognostic value and not rare 
mutations [25]. We found no recent data on the prognostic value of rare BRAF 
mutations in the adjuvant setting. In the metastatic setting, BRAF non V600E-
mutated tumours seem to carry a better prognosis [26]. In the present work, we found 
that only KRAS and NRAS codon 61 mutations had significant negative prognostic 
  value, while other rare RAS or BRAF non V600E mutations did not seem to affect 
patient outcome. However, these results need to be confirmed in larger series with 
full RAS and BRAF mutational analyses. 
In conclusion, adding cetuximab to standard FOLFOX adjuvant therapy in stage III 
colon cancer results in a non significant trend towards better outcomes in RAS & 
BRAF WT patients. No significant detrimental effect was observed in RAS mutant 
patients. Though not significant, the clinically relevant 0.76 adjusted HR observed for 
DFS in favor of adding cetuximab to FOLFOX in full RAS and BRAF WT stage III 
colon cancer pts, may justify a new randomized controlled trial testing EGFR 
inhibitors in this setting. 
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   Figure legends 
Figure 1: 
Distribution of mutations. 
Figure 2: 
 Kaplan Meier curves for time to relapse according to study treatment (A) in the 
KRAS exon 2 WT intention-to-treat population, (B) In patients with RAS WT and 
BRAF WT tumours, and (C) In patients with RAS-mutated tumours. TTR=time to 
recurrence. HR=hazard ratio. 
Figure 3: 
Prognostic impact of individual RAS and BRAF mutations on recurrence (A) and 
survival (B). 
 
Supplementary Figure 1: 
Flow chart of PETACC8 trial molecular study evaluating  the impact of. full RAS and 
BRAF wildtype mutations 
Supplementary Figure 2: 
Kaplan Meier curves for disease-free survival according to study treatment (A) in the 
KRAS exon 2 WT intention-to-treat population, (B) In patients with RAS WT and 
BRAF WT tumours, and (C) In patients with RAS-mutated tumours. DFS=Disease-
Free Survival. HR=hazard ratio. 
 
Table 1- Baseline patient and tumour characteristics in the RAS mutant, BRAF 
mutant and double wildtype subpopulations 
 
 
Double WT RAS Mutant BRAF Mutant 
Folfox Folfox+Cetux Folfox Folfox+Cetux Folfox Folfox+Cetux 
Gender n 367 352 484 484 99 114 
Male 224 (61.0%) 225 (63.9%) 255 (52.7%) 270 (55.8%) 49 (49.5%) 55 (48.2%) 
Female 143 (39.0%) 127 (36.1%) 229 (47.3%) 214 (44.2%) 50 (50.5%) 59 (51.8%) 
Age n 367 352 484 484 99 114 
Mean (SD) 58.83 (9.21) 58.33 (10.12) 60.03 (9.47) 59.68 (9.37) 60.85 (8.86) 59.78 (9.26) 
Median 60.00 60.00 61.00 61.00 62.00 60.00 
Q1; Q3 53.00; 66.00 52.00; 66.00 54.00; 68.00 54.00; 67.00 54.00; 68.00 53.00; 67.00 
Range 25.00; 75.00 19.00; 75.00 25.00; 75.00 23.00; 74.00 28.00; 73.00 27.00; 74.00 
Age  n 367 352 484 484 99 114 
Age <= 70 years 336 (91.6%) 318 (90.3%) 425 (87.8%) 429 (88.6%) 89 (89.9%) 99 (86.8%) 
Age > 70 years 31 (8.4%) 34 (9.7%) 59 (12.2%) 55 (11.4%) 10 (10.1%) 15 (13.2%) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
WHO 
Performance 
Status 
n 355 344 463 465 96 108 
0 293 (82.5%) 284 (82.6%) 387 (83.6%) 380 (81.7%) 73 (76.0%) 83 (76.9%) 
1 60 (16.9%) 60 (17.4%) 75 (16.2%) 83 (17.8%) 23 (24.0%) 25 (23.1%) 
2 2 (0.6%) 0 (0.0) 1 (0.2%) 2 (0.4%) . . 
Tumour Location n 366 352 479 483 99 114 
Left  276 (75.4%) 260 (73.9%) 261 (54.5%) 254 (52.6%) 31 (31.3%) 32 (28.1%) 
Right  88 (24.0%) 91 (25.9%) 211 (44.1%) 216 (44.7%) 67 (67.7%) 82 (71.9%) 
Both sides 2 (0.5%) 1 (0.3%) 7 (1.5%) 13 (2.7%) 1 (1.0%) 0 (0.0) 
Tumour grade n 367 352 483 484 99 114 
Missing 5 (1.4%) 3 (0.9%) 7(1.4%) 6 (1.2%) 1 (1.0%) 2 (1.8%) 
Well 
differentiated 79 (21.5%) 80 (22.7%) 95 (19.7%) 102 (21.1%) 14 (14.1%) 16 (14.0%) 
Moderately 
differentiated 227 (61.9%) 207 (58.8%) 295 (61.1%) 298 (61.6%) 50 (50.5%) 54 (47.4%) 
Poorly 
differentiated 54 (14.7%) 60 (17.0%) 84 (17.4%) 76 (15.7%) 34 (34.3%) 40 (35.1%) 
Undifferentiated 2 (0.5%) 2 (0.6%) 2 (0.4%) 2 (0.4%) 0 (0.0) 2 (1.8%) 
pN  stage n 367 352 484 484 99 114 
pN1 240 (65.4%) 224 (63.6%) 304 (62.8%) 305 (63.0%) 60 (60.6%) 58 (50.9%) 
pN2 127 (34.6%) 128 (36.4%) 180 (37.2%) 179 (37.0%) 39 (39.4%) 56 (49.1%) 
 Double WT RAS Mutant BRAF Mutant 
Folfox Folfox+Cetux Folfox Folfox+Cetux Folfox Folfox+Cetux 
pT stage n 367 352 484 484 99 114 
pT1 11 (3.0%) 10 (2.8%) 14 (2.9%) 10 (2.1%) 1 (1.0%) 2 (1.8%) 
pT2 32 (8.7%) 30 (8.5%) 29 (6.0%) 30 (6.2%) 5 (5.1%) 3 (2.6%) 
pT3 259 (70.6%) 229 (65.1%) 332 (68.6%) 346 (71.5%) 72 (72.7%) 84 (73.7%) 
pT4 65 (17.7%) 83 (23.6%) 109 (22.5%) 98 (20.2%) 21 (21.2%) 24 (21.1%) 
pTis . . . . 0 (0.0) 1 (0.9%) 
Bowel obstruction 
and perforation 
n 367 352 484 484 99 114 
Bowel 
obstruction 
and/or 
perforation 64 (17.4%) 65 (18.5%) 99 (20.5%) 97 (20.0%) 17 (17.2%) 18 (15.8%) 
No bowel 
obstruction and 
no perforation 303 (82.6%) 287 (81.5%) 385 (79.5%) 387 (80.0%) 82 (82.8%) 96 (84.2%) 
VELI n 367 352 484 484 99 114 
Vascular 
Invasion or 
Lymphatic 
infiltration 210 (57.2%) 207 (58.8%) 262 (54.1%) 248 (51.2%) 67 (67.7%) 62 (54.4%) 
No Vascular 
Invasion and no 
Lymphatic 
infiltration 104 (28.3%) 95 (27.0%) 144 (29.8%) 154 (31.8%) 24 (24.2%) 29 (25.4%) 
MMR Status N 340 324 406 390 89 105 
pMMR 309 (90.9%) 301 (92.9%) 377 (92.9%) 372 (95.4%) 56 (62.9%) 71 (67.6%) 
dMMR 31 (9.1%) 23 (7.1%) 29 (7.1%) 18 (4.6%) 33 (37.1%) 34 (32.4%) 
Abbreviations: MMR, mismatch repair; pMMR, proficient MMR; dMMR, deficient MMR  
 
Table 2: RAS and BRAF mutations 
 RAS Mutant  
(n=968) 
BRAF Mutant  
(n=213) 
KRAS mutations   
 Exon 2 783 (80.9%) - 
     Codon 12 594 (75.9%) - 
     Codon 13 178 (18.4%) - 
     Other 11 (1.4%) - 
Exon 3 42 (4.3%) - 
     Codon 59 8 (19.0%) - 
     Codon 61 34 (81.0%) - 
Exon 4 80 (8.3%) - 
     Codon 146 68 (85.0%) - 
     Codon 117 11 (13.8%) - 
     Other 1 (1.2%) - 
NRAS mutations   
Exon 2 30 (3.1%) - 
     Codon 12 26 (86.7%) - 
     Codon 13 4 (13.3%) - 
Exon 3 31 (3.2%) - 
Exon 4 2 (0.2%) - 
BRAF mutations -  
V600E - 192 (90.1%) 
Other mutations - 21 (9.9%) 
 
 
 
  
 
 
Distribution of mutations.  
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Kaplan Meier curves for time to relapse according to study treatment (B) In patients with RAS WT and BRAF 
WT tumours,  
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Kaplan Meier curves for time to relapse according to study treatment (C) In patients with RAS-mutated 
tumours  
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 Supplementary Table 1. Study population compared to all patients enrolled in the 
PETACC8 trial. 
 
Full RAS 
patients 
PETACC8 
patients P-value 
(N=1900) (N=2559)  
Gender n 
1900 2559 
X²:   
0.7923 
Male 1078 (56.7%) 1462 (57.1%) . 
Female 822 (43.3%) 1097 (42.9%) . 
Treatment Group n 
1900 2559 
X²:   
0.9897 
Folfox 950 (50.0%) 1279 (50.0%) . 
Folfox+Cetux 950 (50.0%) 1280 (50.0%) . 
Age n 
1900 2559 
W:   
0.4962 
Mean (SD) 59.42 (9.49) 59.19 (9.67) . 
Median 61.00 60.00 . 
Q1; Q3 54.00; 67.00 53.00; 67.00 . 
Range 19.00; 75.00 19.00; 75.00 . 
Age  n 
1900 2559 
X²:   
0.8422 
Age <= 70 years 1696 (89.3%) 2289 (89.4%) . 
Age > 70 years 204 (10.7%) 270 (10.6%) . 
Missing 0 (0.0) 0 (0.0) . 
WHO performance status n 
1831 2441 
X²:   
0.8073 
0 1500 (81.9%) 2004 (82.1%) . 
1 326 (17.8%) 431 (17.7%) . 
2 5 (0.3%) 5 (0.2%) . 
3 0 (0.0) 1 (0.0%) . 
Tumour Location n 
1893 2546 
X²:   
0.3069 
Left  1114 (58.8%) 1552 (61.0%) . 
Right  755 (39.9%) 968 (38.0%) . 
Both sides 24 (1.3%) 26 (1.0%) . 
 Full RAS 
patients 
PETACC8 
patients P-value 
(N=1900) (N=2559)  
Tumour grade n 
1899 2557 
X²:   
0.9978 
.A 1 (0.1%) 1 (0.0%) . 
.D 3 (0.2%) 5 (0.2%) . 
.K 20 (1.1%) 25 (1.0%) . 
Well differentiated 386 (20.3%) 527 (20.6%) . 
Moderately differentiated 1131 (59.6%) 1527 (59.7%) . 
Poorly differentiated 348 (18.3%) 461 (18.0%) . 
Undifferentiated 10 (0.5%) 11 (0.4%) . 
pN grade n 
1900 2559 
X²:   
0.8501 
pN1 1191 (62.7%) 1597 (62.4%) . 
pN2 709 (37.3%) 962 (37.6%) . 
pT grade n 
1900 2559 
X²:   
0.5889 
pT1 48 (2.5%) 71 (2.8%) . 
pT2 129 (6.8%) 194 (7.6%) . 
pT3 1322 (69.6%) 1768 (69.1%) . 
pT4 400 (21.1%) 522 (20.4%) . 
pTis 1 (0.1%) 1 (0.0%) . 
pTx 0 (0.0) 3 (0.1%) . 
Bowel obstruction and 
perforation 
n 
1900 2559 
X²:   
0.7152 
Bowel obstruction and/or perforation 360 (18.9%) 496 (19.4%) . 
No bowel obstruction and no perforation 1540 (81.1%) 2063 (80.6%) . 
VELI n 
1900 2559 
X²:   
0.8758 
Vascular Invasion or Lymphatic 
infiltration 1056 (55.6%) 1442 (56.4%) . 
No Vascular Invasion and no Lymphatic 
infiltration 550 (28.9%) 729 (28.5%) . 
Abbreviations: MMR, mismatch repair; pMMR, proficient MMR; dMMR, deficient MMR  ; X²:   ; Chi-Square Test; W: Wilcoxon 
Test 
 
 
